MARKET

BCTX

BCTX

Briacell Therapeutics Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.870
+0.160
+3.40%
After Hours: 5.05 +0.18 +3.70% 19:51 05/19 EDT
OPEN
4.700
PREV CLOSE
4.710
HIGH
5.04
LOW
4.510
VOLUME
382.77K
TURNOVER
0
52 WEEK HIGH
12.47
52 WEEK LOW
2.820
MARKET CAP
74.41M
P/E (TTM)
-366.1654
1D
5D
1M
3M
1Y
5Y
BRIEF-Briacell Therapeutics Corp - Adds Additional Clinical Sites To Broaden Patient Access And Further Boost Enrollment
reuters.com · 1d ago
BriaCell Adds Additional Clinical Sites To Broaden Patient Access And Further Boost Enrollment
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.
Benzinga · 1d ago
We're Hopeful That BriaCell Therapeutics (TSE:BCT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. Indeed, BriaCell Therapeutics...
Simply Wall St. · 05/06 19:02
Why Is BriaCell (BCTX) Stock Moving Today?
Investor Place · 04/13 14:34
Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
Benzinga · 04/13 13:28
Why BriaCell Therapeutics Stock Is Surging Today
BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.
Benzinga · 04/13 13:17
BriaCell gains on FDA fast track nod for its targeted breast cancer immunotherapy Bria-IMT
Shares of BriaCell Therapeutics (NASDAQ:BCTX) have added ~7% in premarket trading on Wednesday after the U.S. Food and Drug Administration (FDA) granted a Fast Track status to the clinical-stage biotech
Seekingalpha · 04/13 12:54
BRIEF-BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
reuters.com · 04/13 12:34
More
No Data
Learn about the latest financial forecast of BCTX. Analyze the recent business situations of Briacell Therapeutics Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BCTX stock price target is 20.00 with a high estimate of 25.00 and a low estimate of 15.00.
High25.00
Average20.00
Low15.00
Current 4.870
EPS
Actual
Estimate
-0.040.160.350.55
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 20
Institutional Holdings: 2.77M
% Owned: 18.15%
Shares Outstanding: 15.28M
TypeInstitutionsShares
Increased
5
154.89K
New
2
1.35M
Decreased
1
35.00K
Sold Out
2
15.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Director
Jamieson Bondarenko
President/Chief Executive Officer/Director
William Williams
Chief Financial Officer/Secretary
Gadi Levin
Other
Giuseppe Del Priore
Director
Marc Lustig
Independent Director
Vaughn Embro-Pantalony
Independent Director
Jane Gross
Independent Director
Martin Schmieg
Independent Director
Rebecca Taub
No Data
No Data
About BCTX
BriaCell Therapeutics Corp. is a clinical stage immunotherapy company. The Company is focused on developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors. Its lead drug candidate, Bria-IMT, is a targeted immunotherapy being developed for the treatment of advanced breast cancer. The Company is focused on conducting Phase I/IIa clinical trial of Bria-IMT in a combination study with immune checkpoint inhibitors such as the Incyte drugs retifanlimab, an anti-PD-1 antibody similar to pembrolizumab, and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The Company is also focused on development of Bria-OTS, which is an off-the-shelf personalized immunotherapy based on a patient’s HLA-type. Its other pre- clinical candidates include Bria-Pros, Bria-Lung, Bria-Mel, Bria-TILsRx and others.

Webull offers kinds of Briacell Therapeutics Corp stock information, including NASDAQ:BCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCTX stock methods without spending real money on the virtual paper trading platform.